Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201612-12 Development of lead compound for treatment of Erbitux resistant colon cancer(Oncology, Biologics) [2019-03-18]

Ongoing Project
Section Lead
Preclinical Phase I Phase II Phase III

Development and Market Objectives

Erbitux is the representative targeted anticancer drug for colon cancer patients. Based on the discovering of primary overcoming factor for Erbitux resistance, we aim to develop a new drug for Erbitux resistant colon cancer patients with KRAS wild type. Moreover, we also present diagnosis of predictive biomarker.

Unmet Medical Need & Target Patients

1) Target patients

Erbitux resistant colon cancer patient group with KRAS wild type gene


2) Unmet Medical Needs

- Colorectal cancer (CRC) is the third leading cause of mortality among cancer patients in the Korea, and it has recorded the second highest mortality rate in the world.

- Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world.

There is a lack of radical surgery for metastatic colorectal cancer and 5yr survival rate for colon cancer is less than 5%. Therefore, the need for the breakthrough therapy is huge.

Erbitux is the EGFR targeted therapeutic antibody and used for treatment of KRAS wild type colon cancer patients. Even some patient with wild-type K-Ras gene can be Erbitux non-responder by having BRAF, BRAS, PTEN and PI3K mutation. Currently, there is no treatment available for Erbitux resistant patient group with KRAS WT Gene, which is almost 50% of KRAS WT Gene holders.


Discovered new predictive biomarker for colon cancer patients who are Erbitux non-responder and established of analysis method.

- Secured effective compound in Erbitux resistant colon cancer model

Verified therapeutic effect of effective compound in the biomarker-activated colon cancer animal model.

Biomarker knock out model shows promising signs of overcoming Erbitux resistance.

Validating target patient group and biomarker in patient derived tissue.

Identifying leads compound with improved efficacy and properties (Development status)

Intellectual Property

- Product patent: 3 patents registered in Korea, 2 PCT filed

Biomarker patent: 1 patent filed in Korea, 1 PCT filed

Competitive Advantages

The First-in-class predictive biomarker for Erbitux non-response colon cancer patients

Contact & Company Overview

Related Project

Related Project